The RTK/ERK pathway is associated with prostate cancer risk on the SNP level: A pooled analysis of 41 sets of data from case-control studies

Gene

Volumn 534, Issue 2, 2014, Pages 286-297

  Chen, Yang ^a,b   Li, Tianyu ^a,b   Yu, Xiaoqiang ^a,b,c   Xu, Jianfeng ^d,e,f   Li, Jianling ^a,b   Luo, Dexiang ^a   Mo, Zengnan ^a,b   Hu, Yanling ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c Institute of Urology and Nephrology   (China)

^d FUDAN UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Meta analysis; Polymorphism; Prostate cancer; RTK ERK pathway

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ALLELE; ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CODOMINANCE; DOMINANT GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RECESSIVE GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

B-CELL CLL/LYMPHOMA 2; BCL2; BENIGN PROSTATIC HYPERPLASIA; BPH; CCND1; CHINA NATIONAL KNOWLEDGE INFRASTRUCTURE; CHINAPCA; CHINESE CONSORTIUM FOR PROSTATE CANCER GENETICS; CI; CNKI; CONFIDENCE INTERVAL; CYCLIN D1; EGF; EGFR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; GENE SET ENRICHMENT ANALYSIS; GENOME-WIDE ASSOCIATION STUDIES; GSEA; GWAS; HARDY-WEINBERG EQUILIBRIUM; HWE; IGF1; INSULIN-LIKE GROWTH FACTOR 1; MAPK; META-ANALYSIS; MITOGEN-ACTIVATED PROTEIN KINASE; ODD RATIO; OR; PCA; POLYMORPHISM; PROSTATE CANCER; RAF1; RECEPTOR TYROSINE KINASES; RTK; RTK/ERK PATHWAY; V-RAF-1 MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGF;

ALLELES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 84890431836     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.10.042     Document Type: Article

References (65)

1. Al-Azayzih A., Gao F., Goc A., Somanath P.R. TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem. Biophys. Res. Commun. 2012, 427:165-170.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
4. Comstock C.E., et al. Cyclin D1 splice variants: polymorphism, risk, and isoform specific regulation in prostate cancer. Clin. Cancer Res. 2009, 15:5338-5349.
5. Coppola D., et al. A functional IGF1 receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol. 1994, 14:4588-4595.
6. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J. Cell. Physiol. 1995, 164:214-221.
7. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2002, 2:389-396.
8. Dilly A.K., et al. Platelet-type 12- lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/AKT/NF-κB. Int. J. Cancer 2013, 133:1784-1791.
9. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
10. Fukuda H., et al. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol. Rep. 2007, 18:1155-1163.
11. Gao Y., Pan X., Su T., Mo Z., Cao Y., Gao F. Glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk: a meta-analysis and HuGE review. Eur. J. Cancer 2009, 45:3303-3314.
12. Guo S.T., et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013, 32:1910-1920.
13. Harbord R.M., Egger M., Sterne J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 2006, 25:3443-3457.
14. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
15. Hirata H., et al. Bcl2938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J. Urol. 2009, 181:1907-1912.
16. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 2000, 85:60-67.
17. Hu P., Liu W., Wang L., Yang M., Du J. High circulating VEGF level predicts poor overall survival in lung cancer. J. Cancer Res. Clin. Oncol. 2013, 139(2013):1157-1167.
18. Jacobs E.J., et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17:972-977.
19. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57:43-66.
20. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
21. Jinchao Ge Studies on the Relationship Between Single Nucleotide Polymorphisms and Susceptibility to Prostate Cancer in Chinese Population 2007, 4. Suzhou university.
22. Jung H.Y., Joo H.J., Park J.K., Kim Y.H. The blocking of c-Met signaling induces apoptosis through the increase of p53 protein in lung cancer. Cancer Res. Treat. 2012, 44:251-261.
23. Karamouzis M.V., Papavassiliou A.G. The IGF-1 network in lung carcinoma therapeutics. Trends Mol. Med. 2006, 12:595-602.
24. Kibel A.S., et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008, 68:1179-1186.
25. Kim H.J., Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell Biol. 2004, 5:441-450.
26. Koike H., et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70years or older and metastatic stage. Anticancer Res. 2003, 23:4947-4951.
27. Lai M.T., Chen R.H., Tsai F.J., Wan L., Chen W.C. Glutathione S-transferase M1 gene but not insulin-like growth factor-2 gene or epidermal growth factor gene is associated with prostate cancer. Urol. Oncol. 2005, 23:225-229.
28. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 1997, 127:820-826.
29. Lin C.C., Wu H.C., Tsai F.J., Chen H.Y., Chen W.C. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology 2003, 62:374-377.
30. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. A mice carrying null mutations of the genes encoding insulin-like growth factor 1 (IGF1) and type 1 IGF receptor (IGF1r). Cell 1993, 75:59-72.
31. Long L., Rubin R., Baserga R., Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res. 1995, 55:1006-1009.
32. Mandal R.K., Mittal R.D. Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?. Urol. Oncol. 2012, 30:555-561.
33. McCarron S.L., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002, 62:3369-3372.
34. McKay M.M., Morrison D.K. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113-3121.
35. Menon J., Doebele R.C., Gomes S., Bevilacqua E., Reindl K.M., Rosner M.R. A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One 2012, 7:e49893.
36. Meyer A., et al. Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol. Oncol. 2013, 31:74-81.
37. Ning Q.Y., Wu J.Z., Zang N., Liang J., Hu Y.L., Mo Z.N. Key pathways involved in prostate cancer based on gene set enrichment analysis and meta-analysis. Genet. Mol. Res. 2011, 10:3856-3887.
38. Onen I.H., Konac E., Eroglu M., Guneri C., Biri H., Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position-460 and sporadic prostate cancer in the Turkish population. Mol. Biol. Rep. 2008, 35:17-22.
39. Park Y.H., Seo S.Y., Lee E., Ku J.H., Kim H.H., Kwak C. Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. J. Urol. 2013, 189:1547-1552.
40. Pawson T. Protein modules and signalling networks. Nature 1995, 373:573-580.
41. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 2002, 38(Suppl. 5):S3-S10.
42. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
43. Powles T., et al. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann. Oncol. 2013, 24:2098-2103. (Apr 11).
44. Purcell S., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
45. Resnicoff M., et al. The insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995, 55:2463-2469.
46. Resnicoff M., Huang Z., Herbert D., Abraham D., Baserga R. A novel class of peptides that induce apoptosis and abrogate tumorigenicity in vivo. Biochem. Biophys. Res. Commun. 1997, 240:208-212.
47. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
48. Sarma A.V., et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 2008, 68:296-305.
49. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 13(103):211-225.
50. Schumacher F.R., et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum. Mol. Genet. 2010, 19:3089-3101.
51. Sell C., et al. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblast. Mol. Cell. Biol. 1994, 14:3604-3612.
52. Sfar S., Hassen E., Saad H., Mosbah F., Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006, 35:21-28.
53. Shih M.C., et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012, 31:2389-2400.
54. Tao Y., Pinzi V., Bourhis J., Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 2007, 4:591-602.
55. Teixeira A.L., et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin. Cancer Res. 2008, 14:3367-3371.
56. Tognon C.E., Sorensen P.H. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin. Ther. Targets 2012, 16:33-48.
57. VanCleave T.T., et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 2010, 70:341-352.
58. Vo B.T., Morton D., Komaragiri S., Millena A.C., Leath C., Khan S.A. TGF-β Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K/AKT/mTOR Pathway. Endocrinology 2013, 154(2013):1768-1779.
59. Wang L., et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int. J. Cancer 2003, 103:116-120.
60. Wang X., Chen X., Fang J., Yang C. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int. J. Clin. Exp. Pathol. 2013, 6:586-597.
61. Xu J., et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat. Genet. 2012, 44:1231-1235.
62. Zeigler M.E., Krause S., Karmiol S., Varani J. Growth factor-induced epidermal invasion of the dermis in human skin organ culture: dermal invasion correlated with epithelial cell motility. Invasion Metastasis 1996, 16:3-10.
63. Zhao Z., Zhang J., Li M., Yang Y., Sun K., Wang J. ANP-NPRA signaling pathway-a potential therapeutic target for the treatment of malignancy. Crit. Rev. Eukaryot. Gene Expr. 2013, 23:93-101.
64. Zhao G., et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013, 8:e53906.
65. Zhu G., et al. Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo. Oncol. Lett. 2011, 2:1213-1217.